Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia
| Autor: | Kenneth B. McCredie, Charles Koller, Moshe Talpaz, Hagop M. Kantarjian, Michael J. Keating, Jay Schachner, Susan O'Brien, Craig C. Childs, Emil J. Freireich |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Adult
Male Antimetabolites Antineoplastic Cancer Research medicine.medical_specialty Chronic lymphocytic leukemia Nodular Partial Remission Gastroenterology Drug Administration Schedule Recurrence Fludarabine monophosphate hemic and lymphatic diseases Internal medicine medicine Humans Stage (cooking) Survival rate Aged Neoplasm Staging Aged 80 and over business.industry Remission Induction Middle Aged medicine.disease Leukemia Lymphocytic Chronic B-Cell Surgery Fludarabine Survival Rate Pneumonia Oncology Female business Vidarabine Phosphate Untreated Chronic Lymphocytic Leukemia medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 9:44-49 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.1991.9.1.44 |
| Popis: | Thirty-three patients with chronic lymphocytic leukemia (CLL) with advanced Rai stage (III-IV) or progressive Rai stage (0-II) disease were treated with fludarabine as a single agent. Eleven patients (33%) obtained a complete remission (CR), 13 (39%) a clinical CR with residual nodules as the only evidence of disease (nodular partial remission [PR]), and two patients (6%) achieved a PR for a total response rate of 79%. Response was rapid, usually occurring after three to six courses of treatment. The major morbidity was infection. Febrile episodes occurred in 13% of the courses (pneumonia 6%, minor infection 4%, and transient fever of undocumented cause 3%). Fludarabine appears to be the most cytoreductive single agent so far studied in CLL. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|